RO7049389

DRUG3 trials

Sponsors

Hoffmann-La Roche

Conditions

Healthy VolunteersHepatitis B VirusHepatitis B, Chronic

Phase 1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Participants

CompletedNCT02952924

Hoffmann-La RocheHepatitis B, Chronic

Start: 2016-12-14End: 2022-03-16Updated: 2024-10-31

A Double-Blind Single-Ascending Dose (SAD) and Multiple-Ascending Dose (MAD) Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7049389 in Healthy Chinese Participants

CompletedNCT03570658

Hoffmann-La RocheHepatitis B Virus

Start: 2018-08-24End: 2019-01-28Updated: 2020-02-28

A Study to Investigate the Effect of RO7049389 on the Pharmacokinetics of Pitavastatin in Healthy Volunteers

CompletedNCT03717064

Hoffmann-La RocheHealthy Volunteers

Start: 2018-11-07End: 2018-12-17Updated: 2020-01-10

Related Papers

Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial.

2021-07-0646 citations

A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy Participants.

2020-10-2018 citations